News
Recipharm announces signature of letter of intent for aseptic fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate
Recipharm, a leading contract development and manufacturing organisation (CDMO) announces that it has signed a letter of intent with Moderna, a U.S. based biotech company, to formulate, fill and finish mRNA-1273, Moderna’s COVID-19 vaccine candidate. The activity will be...
News
Patent Protection Lift-off For COVID-19 Vaccines; Not a Bright Choice
The world of Pharmaceuticals is caught in the web of who brings out the vaccine and when scenario. The darkest hours that the world has been a witness to are from the last 10 months. However, every day, there...
News
Idifarma partners with industry expert to strengthen spray drying expertise
SPANISH contract development and manufacturing organisation (CDMO) Idifarma has announced a partnership with Stefano Console from Swiss life sciences consultancy Oriento SA.
Bringing with him the benefit of over 25 years of experience in the pharmaceutical and fine chemical industry,...
Drug Research
Samsung Biologics breaks ground on Super Plant, the world’s largest and most innovative bio-manufacturing facility
Samsung Biologics officially began construction of its Plant 4 in Incheon, South Korea. Dubbed the “Super Plant,” the new, multi-story 238,000-square-meter construction will be the world’s largest biopharmaceutical manufacturing facility of its kind boasting 256,000 liters total manufacturing capacity.
In...
News
A Go-Ahead Given By European Commission To Moderna For Supplying The Budding COVID-19 Vaccine
In its endeavour to further boost up the supplies of COVID-19 doses once they are available for use, the European Commission has approved a contract under the EU Vaccines Strategy, a sixth of the lot with Moderna, the American...
News
The Pistoia Alliance launches user experience maturity model for life sciences
The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life science and healthcare R&D, has launched a free to use UXLS (User Experience in Life Sciences) maturity model. The model will help companies...
Clinical Trials
Bharat Biotech underplays adverse event in Covaxin Phase 1 trial as start date for Phase 3 nears
Bharat Biotech, during its phase 1 trials, experienced an adverse event in a volunteer that it did not promptly admit to the public. As per a statement from the vaccine maker, the event was reported in a timely manner...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read